The Financial Times - Global Pharmaceutical and Biotechnology Conference 2019
Disruption and transformation will continue to be the focus of life science leaders in 2019 and beyond.
Pricing pressures in the US and a growing number of markets globally has already set in motion a search for new and innovative payment models, while the rise of ultra-expensive, potentially curative gene and cell therapies has brought to the fore a heated discussion about the sustainability of industry’s underlying economic and funding model.
With a host of ‘new entrants’ in the shape of big tech and nimble, consumer-centric start-ups nibbling at pharma’s heals in the emerging prevention and wellness space, meanwhile, pharma faces competition on an increasing number of fronts. Success in the new data and patient-centric world which is emerging will increasingly depend on the forging relationships with patients sustained on trust, and building new business models for the future.
FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.
The FT Global Pharmaceutical and Biotechnology Conference will be attended by:
- Pharmaceutical companies
- Biotechnology companies
- Diagnostic and medical device
- Healthcare providers and insurers
- Government healthcare departments, HTA’s and drug regulators
- IT, big data and analytics providers
- Health economists
- Healthcare investment bankers, private equity
- Patient representatives and NGOs